Drugs / danoprevir
danoprevir
also known as
DNV · RO5190591 · ITMN-191 · RG7227 · DANOPREVIR SODIUM · Ganovo · R-05190591 · R-7227 · +2 more
Trials 28 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 118 trials | ||||||
| Phase 1 | NCT03288636 | Aug → Sep 2017 | hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03020134 | Jul → Aug 2016 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03019991 | Oct → Nov 2015 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01714154 | Nov 2012 → May 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01592305 | May → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01588002 | Apr → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01519336 | Feb → Mar 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01531647 | Jan → Mar 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01514968 | Dec 2011 → Feb 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01483729 | Dec 2011 → Jan 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01398293 | Aug → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01418274 | Aug → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01392755 | Jul → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01389544 | Jun → Jul 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01185873 | Feb 2011 → Dec 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01164488 | Jul → Aug 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01185860 | Aug 2009 → Jan 2012 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00801255 | Nov 2008 → Mar 2010 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03020004 | Jan → Nov 2016 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01749150 | Apr 2013 → Feb 2015 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01483742 | Apr 2012 → Sep 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01278134 | Feb 2011 → Oct 2012 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01220947 | Nov 2010 → Dec 2012 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00963885 | Aug 2009 → Jan 2012 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03362814 | Jul 2017 → Dec 2018 | hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03020082 | Jun 2016 → May 2017 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04345276 | Mar → Apr 2020 | COVID-19 | Huoshenshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04291729 | Feb → Mar 2020 | COVID-19 | The Ninth Hospital of Nanchang | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01654211 Comparator | Jul → Nov 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01592318 Comparator | May → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03020095 Background | Aug 2015 → Aug 2016 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01579019 Background | Jul 2012 → Mar 2014 | chronic hepatitis C virus infection | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 2 | NCT01628094 Background | Jun 2012 → Nov 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01331850 Background | May 2011 → Jan 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 39 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danoprevir | “Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection” NCT04291729 ↗32 |
| Known as | DANOPREVIR SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL258734 ↗ |
| Known as | DNV | “between danoprevir (DNV) when coadministered with low-dose ritonavir (r) and tenofovir disoproxil fumarate (TDF) or atazanavir (ATZ) in healthy volunteers” NCT01592305 ↗3“Danoprevir (DNV) is a hepatitis C virus (HCV) protease inhibitor” PMID 24295986 ↗ Dec 2013 “Danoprevir (DNV) 100mg tablet administered orally twice daily” NCT03020004 ↗ “Danoprevir (DNV)administered orally 100mg BID for 12 weeks;” NCT03020082 ↗ |
| Known as | Ganovo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04291729 ↗ |
| Known as | ITMN-191 | “Danoprevir (RG7227; ITMN-191) is a potent inhibitor of the HCV NS3/4A serine protease.” PMID 21354234 ↗ Feb 20111“an HCV protease inhibitor (RO5190591/ITMN-191/danoprevir)” NCT00801255 ↗ |
| Known as | R-05190591 | ChEMBL registry synonym — accepted as the source's own label CHEMBL258734 ↗ |
| Known as | R-7227 | ChEMBL registry synonym — accepted as the source's own label CHEMBL258734 ↗ |
| Known as | RG7227 | “Danoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease, which is currently in development in combination with low-dose ritonavir for the...” PMID 23712757 ↗ Sep 20131“Danoprevir (RG7227; ITMN-191) is a potent inhibitor of the HCV NS3/4A serine protease.” PMID 21354234 ↗ Feb 2011 |
| Known as | RO-5190591-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL258734 ↗ |
| Known as | RO5190591 | “an HCV protease inhibitor (RO5190591/ITMN-191/danoprevir)” NCT00801255 ↗ |
| Known as | RO5190591-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL258734 ↗ |
| Action | Inhibit | “danoprevir, an NS3/4A protease inhibitor” PMID 20951424 ↗ Oct 2010 |
| Modality | Small molecule | “an oral Hepatitis C virus protease inhibitor” NCT04345276 ↗ |
| Route | Oral | “up to 13 days oral combination treatment with RG7128 (500 mg or 1000 mg twice daily) and danoprevir” PMID 20951424 ↗ Oct 2010 |